BIIB vs TASK · P/E 21, rev $9.89B vs P/E 4.8, rev $995.0M
Biogen Inc (BIIB) versus Taskus Inc (TASK) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Taskus Inc (TASK) is a information technology services company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported TASK revenue for 2024-12-31 was $995.0M. Net income was $45.9M. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. TASK currently screens at market cap $492.7M and trailing P/E 4.8.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. TASK currently screens at market cap $492.7M and trailing P/E 4.8.
Not investment advice. Open the BIIB and TASK stock pages for the full models.
Not investment advice.